Mitomycin Medac

Mitomycin, the active ingredient in Mitomycin Medac, is an antineoplastic antibiotic presented as a intravesical solution for intravesical use. It treats non‑muscle invasive bladder cancer in adult patients, helping to reduce tumour recurrence after surgical resection.

GNH USA supplies Mitomycin Medac as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Mitomycin is employed in oncology for cancers that respond to DNA‑crosslinking chemotherapy.

Non‑muscle invasive bladder cancer: reduces tumour recurrence and progression after transurethral resection. Gastric cancer: used as part of combination regimens to improve response rates. Pancreatic cancer: administered in systemic protocols to enhance cytotoxic effect.

Mitomycin may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Bladder irritation or dysuria - Hematuria - Urinary frequency - Mild nausea - Fatigue - Transient low blood pressure

Serious or Rare Side Effects: - Severe hemorrhagic cystitis - Bone marrow suppression (neutropenia, thrombocytopenia) - Renal toxicity - Pulmonary fibrosis - Anaphylactic reactions - Life‑threatening infection

Mitomycin requires careful monitoring and specific safety measures before and during therapy. - Renal function assessment: evaluate creatinine clearance prior to each instillation. - Hematologic monitoring: perform complete blood counts regularly to detect marrow suppression. - Avoid concurrent nephrotoxic agents: limit use of cisplatin, aminoglycosides, or high‑dose NSAIDs. - Caution with prior pelvic radiation: increased risk of bladder toxicity. - Pregnancy and breastfeeding: contraindicated due to unknown fetal risk; advise effective contraception. - Store at ambient temperature: keep in the original container, protect from light and moisture.

Mitomycin can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Concurrent myelotoxic chemotherapy (e.g., cyclophosphamide) – heightened bone‑marrow suppression. - High‑dose radiation therapy to the pelvis – increased risk of severe cystitis. - Nephrotoxic drugs (e.g., cisplatin) – additive renal injury.

Moderate Interactions (Monitor Closely): - Anticoagulants (warfarin, DOACs) – enhanced bleeding tendency. - NSAIDs – potential renal function decline. - ACE inhibitors or ARBs – may exacerbate renal impairment. - Drugs affecting bone‑marrow function (azathioprine, methotrexate) – monitor blood counts. - Herbal supplements with anticoagulant properties – assess bleeding risk.